Physiology, pathology and pharmacology of the male reproductive system

Periodontology 2000

Volumn 61, Issue 1, 2013, Pages 232-251

  Mawhinney, Michael ^a   Mariotti, Angelo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN;

ARTICLE; ENDOCRINE GLAND; GENITAL SYSTEM DISEASE; HUMAN; MALE; MALE GENITAL SYSTEM; PHYSIOLOGY; PUBERTY; SEX DIFFERENTIATION; SPERMATOGENESIS; UROGENITAL TRACT DISEASE;

ANABOLIC AGENTS; ANDROGENS; ENDOCRINE GLANDS; GENITAL DISEASES, MALE; GENITALIA, MALE; HUMANS; MALE; MALE UROGENITAL DISEASES; PUBERTY; SEX DIFFERENTIATION; SPERMATOGENESIS;

EID: 84871214023     PISSN: 09066713     EISSN: 16000757     Source Type: Journal    
DOI: 10.1111/j.1600-0757.2011.00408.x     Document Type: Article

References (96)

1. Abel EL. Marihuana and sex: a critical survey. Drug Alcohol Depend 1981: 8: 1-22.
2. Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav 2007: 91: 449-458.
3. Belis JA, Blume CD, Mawhinney MG. Androgen and estrogen binding in male guinea pig accessory sex organs. Endocrinology 1977: 101: 726-740.
4. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984: 132: 474-479.
5. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996: 335: 1-7.
6. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactregulation of release and putative functions. Diabetes Obes Metab 2007: 9: 464-476.
7. Brooks DE. Epididymal functions and their hormonal regulation. Aust J Biol Sci 1983: 36: 205-221.
8. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl 1996: 7: 64-69.
9. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991: 324: 1156-1161.
10. Ceccarelli I, De Padova AM, Fiorenzani P, Massafra C, Aloisi AM. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience 2006: 140: 929-937.
11. Cunha GR, Chung LW, Shannon JM, Reese BA. Stromal-epithelial interactions in sex differentiation. Biol Reprod 1980: 22: 19-42.
12. Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR. The effects of 9-ene- tetrahydrocannabinol on hormone release and immune function. J Steroid Biochem 1989: 34: 263-270.
13. de Lamirande E. Semenogelin, the main protein of the human semen coagulum, regulates sperm function. Semin Thromb Hemost 2007: 33: 60-68.
14. Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol 2006: 254-255: 207-216.
15. Eddy EM, Washburn TF, Bunch DO, Goulding EH, Gladen BC, Lubahn DB, Korach KS. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology 1996: 137: 4796-4805.
16. Fawcett D. Ultrastructure and function of the Sertoli cell. Greep RO, Astwood EB, editors. Handbook of Physiology Section 7 Endocrinology. Washington DC: American Physiological Society, 1975: 21-56.
17. Franks LM. Gross and Microscopic Anatomy. Grayhack JT, Wilson JD, Scherbenske MJ; National Institute of Arthritis M, Digestive D, editors. Benign prostatic hyperplasia : a workshop sponsored by the Kidney Disease and Urology Program of the National Institute of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Bethesda, Maryland, February 20-21, 1975. Washington, DC.
18. Genazzani AR, Petraglia F. Opioid control of luteinizing hormone secretion in humans. J Steroid Biochem 1989: 33: 751-755.
19. Getzenberg RH, Pienta KJ, Coffey DS. The tissue matrix: cell dynamics and hormone action. Endocr Rev 1990: 11: 399-417.
20. Gooren L. The biology of human psychosexual differentiation. Horm Behav 2006: 50: 589-601.
21. Greenberg S, Kadowitz PJ, Schedl HP, Long JP. Effect of age and testosterone on calcium content and reactivity of guinea-pig vas deferens. J Pharmacol Exp Ther 1973: 185: 505-513.
22. Griffin JE, Wilson JD. The Testis. Bondy PK, Rosenberg LE, editors. Metabolic Control and Disease. 8th edition. Philadelphia: W.B. Saunders. 1980: 1535-1578.
23. Grossman A. Opioids and stress in man. J Endocrinol 1988: 119: 377-381.
24. Grumbach M, Conte F. Disorders of sexual differentiation. Williams RH, Wilson JD, Foster DW, editors. Williams' textbook of endocrinology. Philadelphia: W.B. Saunders Co, 1992: 853-952.
25. Grumbach MM, Richards GE, Conte FA, Kalplan SL. Clinical disorders of adrenal function and puberty: an assessment of the role of the adrenal cortex in normal and abnormal puberty in man and evidence for an ACTH-like pituitary adrenal androgen stimulating hormone. James VHT, Serio M, Giusti G, Martini L, editors. The Endocrine Function of the Human Adrenal. Cortex, Proceedings of the Serono Symposia. New York: Academic Press, 1978: 18: 583-612.
26. Hadi HA, Hill JA, Castillo RA. Alcohol and reproductive function: a review. Obstet Gynecol Surv 1987: 42: 69-74.
27. Hammond GL, Bocchinfuso WP. Sex hormone-binding globulgene organization and structure/function analyses. Horm Res 1996: 45: 197-201.
28. Hansson V, Rutzen M, French F, Nayfeh S. Androgen transport and receptor mechanisms in testis and epididymus. Washington DC: American Physiological Society, 1975.
29. Harclerode J. Endocrine effects of marijuana in the male: preclinical studies. NIDA Res Monogr 1984: 44: 46-64.
30. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004: 34: 513-554.
31. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974: 38: 476-479.
32. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004: 101: 894-904.
33. Hohbach C, Ueberberg H. Ultrastructural and histochemical aspects of prostatic secretion in dog. Pathol Res Pract 1982: 173: 225-235.
34. Howlett TA, Rees LH. Endogenous opioid peptides and hypothalamo-pituitary function. Annu Rev Physiol 1986: 48: 527-536.
35. Huggins C, Webster WO. Duality of human prostate in response to estrogen. J Urol 1948: 59: 258-266.
36. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002: 198: 51-59.
37. Isaacs JT, Isaacs WB, Wheaton LG, Coffey DS. Differential effects of estrogen treatment on canine seminal plasma components. Invest Urol 1980: 17: 495-498.
38. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003: 9: 1980-1989.
39. Jones ME, Boon WC, Proietto J, Simpson ER. Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol Metab 2006: 17: 55-64.
40. Josso N, Boussin L, Knebelmann B, Nihoul-Fekete C, Picard JY. Anti-Mullerian hormone and intersex states. Trends Endocrinol Metab 1991: 2: 227-233.
41. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Recent Prog Horm Res 1953: 8: 379-418.
42. Kastelan D, Giljevic Z, Kraljevic I, Korsic M. Selective estrogen receptor modulators: a possible new treatment of osteoporosis in males. Med Hypotheses 2006: 67: 1052-1053.
43. Kim J, Cole D, Johnson A, Centenera V, Schenkman E, Durham J, Azzaro A, Mawhinney M. Androgen induced norepinephrine release from postganglionic neurons mediates accessory sex organ smooth muscle proliferation. J Urol 2002: 167: 1897-1904.
44. Kletter GB, Foster CM, Beitins IZ, Marshall JC, Kelch RP. Acute effects of testosterone infusion and naloxone on luteinizing hormone secretion in normal men. J Clin Endocrinol Metab 1992: 75: 1215-1219.
45. Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R. Male development of chromosomally female mice transgenic for Sry. Nature 1991: 351: 117-121.
46. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981: 41: 3874-3876.
47. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996: 335: 533-539.
48. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007: 249: 30-39.
49. MacDonald A, McGrath JC. Post-natal development of functional neurotransmission in rat vas deferens. Br J Pharmacol 1984: 82: 25-34.
50. Makarov DV, Carter HB. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol 2006: 176: 2383-2385.
51. Mariotti A. Sex steroid hormones and cell dynamics in the periodontium. Crit Rev Oral Biol Med 1994: 5: 27-53.
52. Mariotti A, Durham J, Frederickson R, Miller R, Butcher F, Mawhinney M. Actions and interactions of estradiol and retinoic acid in mouse anterior prostate gland. Biol Reprod 1987: 37: 1023-1035.
53. Mariotti A, Durham J, Mawhinney M. Protein kinases and the androgen-induced proliferation of accessory sex organ smooth muscle. Biol Reprod 1992: 46: 551-560.
54. Mawhinney MG. Etiological considerations for the growth of stroma in benign prostatic hyperplasia. Fed Proc 1986: 45: 2615-2617.
55. Mawhinney MG, Neubauer BL. Actions of estrogen in the male. Invest Urol 1979: 16: 409-420.
56. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998: 338: 557-563.
57. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003: 349: 2387-2398.
58. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003: 61: 3-7.
59. McNeal JE. Normal and pathologic anatomy of prostate. Urology 1981: 17: 11-16.
60. Meachem SJ, Nieschlag E, Simoni M. Inhibin B in male reproduction: pathophysiology and clinical relevance. Eur J Endocrinol 2001: 145: 561-571.
61. Mikhailichenko VV, Esipov AS. Peculiarities of semen coagulation and liquefaction in males from infertile couples. Fertil Steril 2005: 84: 256-259.
62. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990: 143: 747-752.
63. Rajfer J, Coffey DS. Sex steroid imprinting of the immature prostate. Long-term effects. Invest Urol 1978: 16: 186-190.
64. Rodriguez-Pacheco F, Martinez-Fuentes AJ, Tovar S, Pinilla L, Tena-Sempere M, Dieguez C, Castano JP, Malagon MM. Regulation of pituitary cell function by adiponectin. Endocrinology 2007: 148: 401-410.
65. Rosenkrantz H, Esber HJ. Cannabinoid-induced hormone changes in monkeys and rats. J Toxicol Environ Health 1980: 6: 297-313.
66. Rubens R, Dhont M, Vermeulen A. Further studies on Leydig cell function in old age. J Clin Endocrinol Metab 1974: 39: 40-45.
67. Ryan A. Athletics. New York: Springer-Verlag, 1976.
68. Sandfort TG. Sexual orientation and gender: stereotypes and beyond. Arch Sex Behav 2005: 34: 595-611.
69. Schneider JE. Energy balance and reproduction. Physiol Behav 2004: 81: 289-317.
70. Scott WW, Coffey DS. Nonsurgical treatment of human benign prostatic hyperplasia. Vitam Horm 1975: 33: 439-465.
71. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992: 147: 1293-1297.
72. Sikkink J, Fleming M. Health effects of alcohol. St Louis: Mosby-Yearbook, 1992.
73. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-Badge R, Goodfellow PN. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA- binding motif. Nature 1990: 346: 240-244.
74. Stearns EL, MacDonnell JA, Kaufman BJ, Padua R, Lucman TS, Winter JS, Faiman C. Declining testicular function with age. Hormonal and clinical correlates. Am J Med 1974: 57: 761-766.
75. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001: 58: 17-24. discussion 24.
76. Steger RW, Murphy LL, Bartke A, Smith MS. Effects of psychoactive and nonpsychoactive cannabinoids on the hypothalamic-pituitary axis of the adult male rat. Pharmacol Biochem Behav 1990: 37: 299-302.
77. Stutz G, Zamudio J, Santillan ME, Vincenti L, de Cuneo MF, Ruiz RD. The effect of alcohol, tobacco, and aspirin consumption on seminal quality among healthy young men. Arch Environ Health 2004: 59: 548-552.
78. Sufrin G, Coffey DS. A new model for studying the effect of drugs on prostatic growth. 1. Antiandrogens and DNA synthesis. Invest Urol 1973: 11: 45-54.
79. Tanner J. A history of the study of human growth. New York: Cambridge University Press, 1981.
80. Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 2001: 22: 657-674.
81. Terasawa E, Fernandez DL. Neurobiological mechanisms of the onset of puberty in primates. Endocr Rev 2001: 22: 111-151.
82. Van Vugt DA, Meites J. Influence of endogenous opiates on anterior pituitary function. Fed Proc 1980: 39: 2533-2538.
83. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004: 25: 389-425.
84. Viger RS, Silversides DW, Tremblay JJ. New insights into the regulation of mammalian sex determination and male sex differentiation. Vitam Horm 2005: 70: 387-413.
85. Vigier B, Forest MG, Eychenne B, Bezard J, Garrigou O, Robel P, Josso N. Anti-Mullerian hormone produces endocrine sex reversal of fetal ovaries. Proc Natl Acad Sci U S A 1989: 86: 3684-3688.
86. von der Pahlen B. The role of alcohol and steroid hormones in human aggression. Vitam Horm 2005: 70: 415-437.
87. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979: 17: 159-163.
88. Warne GL, Zajac JD. Disorders of sexual differentiation. Endocrinol Metab Clin North Am 1998: 27: 945-967.
89. Warren MP. The effects of exercise on pubertal progression and reproductive function in girls. J Clin Endocrinol Metab 1980: 51: 1150-1157.
90. Wasson JH. Finasteride to prevent morbidity from benign prostatic hyperplasia. N Engl J Med 1998: 338: 612-613.
91. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007: 67: 312-329.
92. Wilson JD. Androgen abuse by athletes. Endocr Rev 1988: 9: 181-199.
93. Wilson JD. Androgens, androgen receptors, and male gender role behavior. Horm Behav 2001: 40: 358-366.
94. Wilson JD. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 2001: 13: 673-678.
95. Wilson JD, George FW, Griffin JE. The hormonal control of sexual development. Science 1981: 211: 1278-1284.
96. Zirkin BR, Chen H. Regulation of Leydig cell steroidogenic function during aging. Biol Reprod 2000: 63: 977-981.